<p>Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age</p>-Reference-Cited by-同舟云学术

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age

Published:2020-06 Issue: Volume:Volume 14 Page:2149-2158
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Parini Rossella^ORCID,Pintos-Morell Guillem^ORCID,Hennermann Julia B,Hsu Ting-Rong^ORCID,Karabul Nesrin,Kalampoki Vasiliki,Gurevich Andrey,Ramaswami Uma^ORCID

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference23 articles.

1. Natural History of Fabry Renal Disease

2. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

3. Cardiac manifestations of Anderson–Fabry disease in heterozygous females

4. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey

5. Time delays in the diagnosis and treatment of Fabry disease

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan;Molecular Genetics and Metabolism Reports;2024-09

2. Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey;Molecular Genetics and Metabolism;2024-09

3. Prevalencia de la enfermedad de Fabry en los pacientes con hipertrofia ventricular izquierda e insuficiencia renal (PrEFaCe);Medicina Clínica;2024-08

4. A systematic literature review on the health-related quality of life and economic burden of Fabry disease;Orphanet Journal of Rare Diseases;2024-04-30

5. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data;Drug Design, Development and Therapy;2024-04